Cargando…

Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis

PURPOSE: Low-dose whole lung radiation therapy (LDLR) has been proposed as a treatment for patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection, and clinical trials are underway. There is an urgent need for preclinical evidence to justify this approach and inform do...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Mark R., Stevenson, Katrina, Chahal, Sandeep K., Curley, Emer, Finney, George E., Gutierrez-Quintana, Rodrigo, Onwubiko, Evarest, Rupp, Angie, Strathdee, Karen, Williams, Karin, MacLeod, Megan K.L., McSharry, Charles, Chalmers, Anthony J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier, Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406661/
https://www.ncbi.nlm.nih.gov/pubmed/34478832
http://dx.doi.org/10.1016/j.ijrobp.2021.08.029
_version_ 1783746539993169920
author Jackson, Mark R.
Stevenson, Katrina
Chahal, Sandeep K.
Curley, Emer
Finney, George E.
Gutierrez-Quintana, Rodrigo
Onwubiko, Evarest
Rupp, Angie
Strathdee, Karen
Williams, Karin
MacLeod, Megan K.L.
McSharry, Charles
Chalmers, Anthony J.
author_facet Jackson, Mark R.
Stevenson, Katrina
Chahal, Sandeep K.
Curley, Emer
Finney, George E.
Gutierrez-Quintana, Rodrigo
Onwubiko, Evarest
Rupp, Angie
Strathdee, Karen
Williams, Karin
MacLeod, Megan K.L.
McSharry, Charles
Chalmers, Anthony J.
author_sort Jackson, Mark R.
collection PubMed
description PURPOSE: Low-dose whole lung radiation therapy (LDLR) has been proposed as a treatment for patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection, and clinical trials are underway. There is an urgent need for preclinical evidence to justify this approach and inform dose, scheduling, and mechanisms of action. METHODS AND MATERIALS: Female C57BL/6 mice were treated with intranasal bleomycin sulfate (7.5 or 11.25 units/kg, day 0) and then exposed to whole lung radiation therapy (0.5, 1.0, or 1.5 Gy, or sham; day 3). Bodyweight was measured daily, and lung tissue was harvested for histology and flow cytometry on day 10. Computed tomography lung imaging was performed before radiation (day 3) and pre-endpoint (day 10). RESULTS: Bleomycin caused pneumonitis of variable severity, which correlated with weight loss. LDLR at 1.0 Gy was associated with a significant increase in the proportion of mice recovering to 98% of initial bodyweight, and a proportion of these mice exhibited less severe histopathologic lung changes. Mice experiencing moderate initial weight loss were more likely to respond to LDLR than those experiencing severe initial weight loss. In addition, LDLR (1.0 Gy) significantly reduced bleomycin-induced increases in interstitial macrophages, CD103+ dendritic cells (DCs), and neutrophil-DC hybrids. Overall, bleomycin-treated mice exhibited significantly higher percentages of nonaerated lung in left than right lungs, and LDLR (1.0 Gy) limited further reductions in aerated lung volume in right but not left lungs. LDLR at 0.5 and 1.5 Gy did not improve bodyweight, flow cytometric, or radiologic readouts of bleomycin-induced pneumonitis. CONCLUSIONS: Our data support the concept that LDLR can ameliorate acute inflammatory lung injury, identify 1.0 Gy as the most effective dose, and provide evidence that it is more effective in the context of moderate than severe pneumonitis. Mechanistically, LDLR at 1.0 Gy significantly suppressed bleomycin-induced accumulation of pulmonary interstitial macrophages, CD103+ DCs, and neutrophil-DC hybrids.
format Online
Article
Text
id pubmed-8406661
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier, Inc
record_format MEDLINE/PubMed
spelling pubmed-84066612021-08-31 Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis Jackson, Mark R. Stevenson, Katrina Chahal, Sandeep K. Curley, Emer Finney, George E. Gutierrez-Quintana, Rodrigo Onwubiko, Evarest Rupp, Angie Strathdee, Karen Williams, Karin MacLeod, Megan K.L. McSharry, Charles Chalmers, Anthony J. Int J Radiat Oncol Biol Phys COVID-19 Scientific Communication PURPOSE: Low-dose whole lung radiation therapy (LDLR) has been proposed as a treatment for patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection, and clinical trials are underway. There is an urgent need for preclinical evidence to justify this approach and inform dose, scheduling, and mechanisms of action. METHODS AND MATERIALS: Female C57BL/6 mice were treated with intranasal bleomycin sulfate (7.5 or 11.25 units/kg, day 0) and then exposed to whole lung radiation therapy (0.5, 1.0, or 1.5 Gy, or sham; day 3). Bodyweight was measured daily, and lung tissue was harvested for histology and flow cytometry on day 10. Computed tomography lung imaging was performed before radiation (day 3) and pre-endpoint (day 10). RESULTS: Bleomycin caused pneumonitis of variable severity, which correlated with weight loss. LDLR at 1.0 Gy was associated with a significant increase in the proportion of mice recovering to 98% of initial bodyweight, and a proportion of these mice exhibited less severe histopathologic lung changes. Mice experiencing moderate initial weight loss were more likely to respond to LDLR than those experiencing severe initial weight loss. In addition, LDLR (1.0 Gy) significantly reduced bleomycin-induced increases in interstitial macrophages, CD103+ dendritic cells (DCs), and neutrophil-DC hybrids. Overall, bleomycin-treated mice exhibited significantly higher percentages of nonaerated lung in left than right lungs, and LDLR (1.0 Gy) limited further reductions in aerated lung volume in right but not left lungs. LDLR at 0.5 and 1.5 Gy did not improve bodyweight, flow cytometric, or radiologic readouts of bleomycin-induced pneumonitis. CONCLUSIONS: Our data support the concept that LDLR can ameliorate acute inflammatory lung injury, identify 1.0 Gy as the most effective dose, and provide evidence that it is more effective in the context of moderate than severe pneumonitis. Mechanistically, LDLR at 1.0 Gy significantly suppressed bleomycin-induced accumulation of pulmonary interstitial macrophages, CD103+ DCs, and neutrophil-DC hybrids. Elsevier, Inc 2022-01-01 /pmc/articles/PMC8406661/ /pubmed/34478832 http://dx.doi.org/10.1016/j.ijrobp.2021.08.029 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle COVID-19 Scientific Communication
Jackson, Mark R.
Stevenson, Katrina
Chahal, Sandeep K.
Curley, Emer
Finney, George E.
Gutierrez-Quintana, Rodrigo
Onwubiko, Evarest
Rupp, Angie
Strathdee, Karen
Williams, Karin
MacLeod, Megan K.L.
McSharry, Charles
Chalmers, Anthony J.
Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis
title Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis
title_full Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis
title_fullStr Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis
title_full_unstemmed Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis
title_short Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis
title_sort low-dose lung radiation therapy for covid-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis
topic COVID-19 Scientific Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406661/
https://www.ncbi.nlm.nih.gov/pubmed/34478832
http://dx.doi.org/10.1016/j.ijrobp.2021.08.029
work_keys_str_mv AT jacksonmarkr lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT stevensonkatrina lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT chahalsandeepk lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT curleyemer lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT finneygeorgee lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT gutierrezquintanarodrigo lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT onwubikoevarest lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT ruppangie lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT strathdeekaren lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT williamskarin lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT macleodmegankl lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT mcsharrycharles lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis
AT chalmersanthonyj lowdoselungradiationtherapyforcovid19lungdiseaseapreclinicalefficacystudyinableomycinmodelofpneumonitis